Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.

What Was Tested

The paper reports a study of Analgesics in the context of migraine, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Analgesics study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Analgesics.

The comparison arm used a placebo, so changes seen with Analgesics could be set against what happens without it.

Endpoints were 2-24-hour sustained pain freedom and no adverse events from 0-24 hours (SPF24NAE), 2-24 hour sustained pain relief and no adverse events from 0-24 hours (SPR24NAE), pain freedom at 2 hours and no adverse events from 0-24 hours (PF2NAE), and pain relief at 2 hours and no adverse events from 0-24 hours (PR2NAE).

What Was Measured

PubMed files the paper under topics including Analgesics, Azepines, Calcitonin Gene-Related Peptide Receptor Antagonists, Imidazoles, Migraine Disorders, Oxazolidinones and Pain.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Analgesics in people with migraine.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Cephalalgia : an international journal of headache), a journal based in England.

More context: Migraine research.